Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Rheumatoid Arthritis

Trial Profile

An Observational, Prospective Cohort Study to Evaluate Safety and Efficacy of Remsima in Patients With Rheumatoid Arthritis

Status: Discontinued
Phase of Trial: Phase IV

Latest Information Update: 09 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Infliximab (Primary) ; Anti-TNF monoclonal antibodies
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Celltrion
  • Most Recent Events

    • 09 Feb 2024 Status changed from recruiting to discontinued.
    • 12 Jul 2021 Results of a pooled analysis assessing long-term safety and effectiveness over 5 years from three observational studies: NCT02557295, NCT02326155 and NCT02557308 published in the Advances in Therapy
    • 30 Apr 2020 Results of post marketing pooled analysis of six observational studies published in the BioDrugs
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top